D. E. Shaw & Co., Inc. Editas Medicine, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 550,853 shares of EDIT stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

550,853

Previous 1,089,240 49.43%

Holding current value

$1.8 Million

Previous $8.08 Million 68.18%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $2.51 Million - $3.92 Million	-538,387 Reduced 49.43%	550,853 $2.57 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $691,217 - $1.09 Million	-98,324 Reduced 8.28%	1,089,240 $8.08 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $3.24 Million - $5.76 Million	518,819 Added 77.58%	1,187,564 $12 Million
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $811,882 - $1.09 Million	-117,324 Reduced 14.93%	668,745 $5.22 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $1.83 Million - $3.3 Million	287,279 Added 57.6%	786,069 $6.47 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $57,392 - $94,130	-8,164 Reduced 1.61%	498,790 $3.62 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $2.84 Million - $4.51 Million	341,333 Added 206.09%	506,954 $4.5 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $2.3 Million - $3.67 Million	-189,204 Reduced 53.32%	165,621 $2.03 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $2.78 Million - $5.94 Million	-278,086 Reduced 43.94%	354,825 $4.2 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $3.8 Million - $7.45 Million	269,778 Added 74.29%	632,911 $12 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $6.14 Million - $9.39 Million	231,386 Added 175.63%	363,133 $9.64 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $415,555 - $771,851	10,582 Added 8.73%	131,747 $5.41 Million
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $15 Million - $27.2 Million	-479,643 Reduced 79.83%	121,165 $6.86 Million
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $32.1 Million - $73.2 Million	-808,285 Reduced 57.36%	600,808 $25.2 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $11.1 Million - $34.6 Million	410,086 Added 41.05%	1,409,093 $98.8 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $7.79 Million - $10.3 Million	-277,634 Reduced 21.75%	999,007 $28 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $4.32 Million - $8.02 Million	233,592 Added 22.4%	1,276,641 $37.8 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $5.45 Million - $12 Million	-365,947 Reduced 25.97%	1,043,049 $20.7 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $8.41 Million - $14.1 Million	431,392 Added 44.13%	1,408,996 $41.7 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $7.97 Million - $9.5 Million	354,273 Added 56.84%	977,604 $22.2 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $3.95 Million - $5.36 Million	193,031 Added 44.86%	623,331 $15.4 Million
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $713,994 - $970,488	-36,747 Reduced 7.87%	430,300 $10.5 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $76,288 - $133,327	-4,194 Reduced 0.89%	467,047 $10.6 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $2.21 Million - $3.07 Million	-79,879 Reduced 14.49%	471,241 $15 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $52,909 - $69,101	1,685 Added 0.31%	551,120 $19.7 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $9.08 Million - $13.4 Million	304,317 Added 124.15%	549,435 $18.2 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $804,785 - $1.15 Million	36,765 Added 17.65%	245,118 $7.53 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $3.29 Million - $5 Million	208,353	208,353 $5 Million

Others Institutions Holding EDIT

# of Institutions

252

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $225M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account